CK0801
Autoimmune & Inflammatory Disorders (e.g., Lupus, GVHD, Crohn's)
Phase 1Active
Key Facts
Indication
Autoimmune & Inflammatory Disorders (e.g., Lupus, GVHD, Crohn's)
Phase
Phase 1
Status
Active
Company
About Cellenkos
Cellenkos is a private, clinical-stage biotech focused on pioneering allogeneic, tissue-targeted T-regulatory cell therapies for autoimmune and inflammatory conditions. Its core technology is a proprietary platform for manufacturing cord blood-derived Tregs, licensed from MD Anderson Cancer Center, with its lead program CK0801 in clinical development. The company is backed by Golden Meditech Holdings Ltd and has established its own cGMP manufacturing facility. Cellenkos aims to address significant unmet medical needs in rare inflammatory diseases with its potentially safer, more accessible 'off-the-shelf' cell therapy approach.
View full company profile